March 9, 2020 — Almirall, S.A. (ALM) announced today that the U.S. Food and Drug Administration (FDA) has completed its filing review and determined that the New Drug Application (NDA) for tirbanibulin, also known as ALM147891, for the treatment of…Original Article
Almirall Announces FDA Acceptance for Filing of U.S. New Drug Application (NDA) for Tirbanibulin in Actinic Keratosis
